These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 11827989

  • 1. Tumor immunotherapy: inching toward the finish line.
    Curiel TJ, Curiel DT.
    J Clin Invest; 2002 Feb; 109(3):311-2. PubMed ID: 11827989
    [No Abstract] [Full Text] [Related]

  • 2. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 3. Cancer immunotherapy with mRNA-transfected dendritic cells.
    Gilboa E, Vieweg J.
    Immunol Rev; 2004 Jun; 199():251-63. PubMed ID: 15233739
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [mRNA-transfected dendritic cells: a promising strategy in immunotherapy].
    Maisnier-Patin K, Crabé S, Breton G, Dupuy FP, Yassine-Diab B, Sékaly RP.
    Med Sci (Paris); 2007 Mar; 23(3):279-84. PubMed ID: 17349289
    [Abstract] [Full Text] [Related]

  • 6. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E.
    Prostate Cancer Prostatic Dis; 2007 Mar; 10(3):224-36. PubMed ID: 17420764
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 8. Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.
    Le Gallo M, Toutirais O, Montier T, Cabillic F, Bouet F, Delépine P, Lehn P, Jotereau F, Catros V.
    J Gene Med; 2008 Jun 15; 10(6):628-36. PubMed ID: 18338820
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.
    Clin Cancer Res; 2005 Aug 01; 11(15):5566-71. PubMed ID: 16061874
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
    Kalady MF, Onaitis MW, Padilla KM, Emani S, Tyler DS, Pruitt SK.
    J Surg Res; 2002 Jun 01; 105(1):17-24. PubMed ID: 12069496
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
    Van Meirvenne S, Dullaers M, Heirman C, Straetman L, Michiels A, Thielemans K.
    Mol Ther; 2005 Nov 01; 12(5):922-32. PubMed ID: 16257383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.